Limited value of routine chest X-rays before biologic therapy in CRSwNP.

IF 1.1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Danish medical journal Pub Date : 2026-08-18 DOI:10.61409/A02260087

Kumanan Rune Nanthan, Vibeke Backer, Skala Dehlair Kalid, Anette Drøhse Kjeldsen

{"title":"Limited value of routine chest X-rays before biologic therapy in CRSwNP.","authors":"Kumanan Rune Nanthan, Vibeke Backer, Skala Dehlair Kalid, Anette Drøhse Kjeldsen","doi":"10.61409/A02260087","DOIUrl":null,"url":null,"abstract":"Introduction: Biologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) have been approved in Denmark since 2022. Chest X-ray (CXR) was implemented by the Global Airways Steering Group as pre-treatment screening to identify pulmonary conditions and monitor adverse effects. This study evaluates the utility of routine CXR screening before initiating biological therapy in patients with CRSwNP.Methods: Baseline data, including chest X-ray, were collected prospectively in the nationwide Global Airways Registry (approved by the Danish Research Ethics Committee R. no.: H-21020685) and analysed in May 2025.Results: A total of 511 patients (335 males, 176 females; mean age 46.5 ± 14.6) years were identified and included in this study; 247 patients were initiated on biologic therapy. In the treatment group, 136 (55%) had normal CXRs, and 12 (5%) had abnormal findings. Among the 264 patients who did not receive biologic treatment, 143 (54%) had normal CXRs and ten (4%) demonstrated abnormal findings.Conclusions: Routine baseline CXR screening before biologic therapy in patients with CRSwNP identified few abnormal findings. Accordingly, routine CXR is likely to offer limited clinical benefit.Funding: The Global Airways database is funded by GlaxoSmithKline, Sanofi and Astra Zeneca. None of the pharmaceutical companies has access to data.Trial registration: Not relevant.","PeriodicalId":11119,"journal":{"name":"Danish medical journal","volume":"73 9","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61409/A02260087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Biologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) have been approved in Denmark since 2022. Chest X-ray (CXR) was implemented by the Global Airways Steering Group as pre-treatment screening to identify pulmonary conditions and monitor adverse effects. This study evaluates the utility of routine CXR screening before initiating biological therapy in patients with CRSwNP.

Methods: Baseline data, including chest X-ray, were collected prospectively in the nationwide Global Airways Registry (approved by the Danish Research Ethics Committee R. no.: H-21020685) and analysed in May 2025.

Results: A total of 511 patients (335 males, 176 females; mean age 46.5 ± 14.6) years were identified and included in this study; 247 patients were initiated on biologic therapy. In the treatment group, 136 (55%) had normal CXRs, and 12 (5%) had abnormal findings. Among the 264 patients who did not receive biologic treatment, 143 (54%) had normal CXRs and ten (4%) demonstrated abnormal findings.

Conclusions: Routine baseline CXR screening before biologic therapy in patients with CRSwNP identified few abnormal findings. Accordingly, routine CXR is likely to offer limited clinical benefit.

Funding: The Global Airways database is funded by GlaxoSmithKline, Sanofi and Astra Zeneca. None of the pharmaceutical companies has access to data.

Trial registration: Not relevant.

查看原文本刊更多论文

CRSwNP生物治疗前常规胸部x线检查价值有限。

自2022年以来，慢性鼻窦炎伴鼻息肉（CRSwNP）的生物疗法已在丹麦获得批准。全球航空指导小组实施了胸部x光检查（CXR），作为治疗前筛查，以确定肺部疾病并监测不良反应。本研究评估了CRSwNP患者在开始生物治疗前进行常规CXR筛查的效用。方法：基线数据，包括胸部x线，在全国全球航空登记（由丹麦研究伦理委员会R. no. 1批准）中前瞻性收集。编号：H-21020685)，并于2025年5月进行分析。结果：共纳入511例患者，其中男性335例，女性176例，平均年龄46.5±14.6岁；247例患者开始生物治疗。在治疗组中，136例（55%）的cxr正常，12例（5%）的cxr异常。在264例未接受生物治疗的患者中，143例（54%）的cxr表现正常，10例（4%）表现异常。结论：CRSwNP患者在生物治疗前进行常规基线CXR筛查，发现很少有异常发现。因此，常规的CXR可能提供有限的临床益处。资助：全球航空数据库由葛兰素史克、赛诺菲和阿斯利康资助。没有一家制药公司可以访问这些数据。试验注册：不相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Danish medical journal MEDICINE, GENERAL & INTERNAL-

CiteScore

2.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： The Danish Medical Journal (DMJ) is a general medical journal. The journal publish original research in English – conducted in or in relation to the Danish health-care system. When writing for the Danish Medical Journal please remember target audience which is the general reader. This means that the research area should be relevant to many readers and the paper should be presented in a way that most readers will understand the content. DMJ will publish the following articles: • Original articles • Protocol articles from large randomized clinical trials • Systematic reviews and meta-analyses • PhD theses from Danish faculties of health sciences • DMSc theses from Danish faculties of health sciences.